RESEARCHER PROFILE
Dr Mark Adams, Senior Research Fellow
School of Biomedical Sciences & Centre for Genomics and Personalised Health
Queensland University of Technology (QUT)
Dr. Mark Adams is a researcher at Queensland University of Technology, working within the School of Biomedical Sciences and Faculty of Health, as well as the Centre of Genomics and Personalised Health. He has been with the university for the past decade, and his main research focus is on lung cancers. Dr. Adams completed his undergraduate studies at the Queensland University of Technology and then went on to earn his PhD based at the Mater Research Institute at the Mater hospital. His PhD focused on prostate cancer and specifically looked at developing drugs that would stop the metastasis of prostate cancer towards the bone.
After completing his PhD, Dr. Adams returned to Queensland University of Technology to commence a postdoctoral fellowship. During his fellowship, he looked at lung cancer and how our genomes are maintained through a process called DNA repair. Dr. Adams has been successful in attracting funding to support his salary through fellowship support from foundations such as Cure Cancer, National Health and Medical Research Council, and the Queensland government.
Dr. Adams’ research focus is on lung cancer, which is the deadliest of all cancers worldwide. He is working towards developing personalised approaches to pinpoint a therapy that is going to be most effective for the person with that disease. Dr. Adams’ research is focusing on chemotherapy and targeted therapy, and he is trying to identify upfront which of those tumours are likely to be resistant to the therapy. He then identifies strategies that will resensitize or increase the sensitivity of the tumour to the standard of care that is targeted therapy or chemotherapy.
Dr. Adams’ research is driven by his fascination with trying to understand how something works and, in particular, understanding cells and the molecular mechanisms underpinning how those cells work. He has always been interested in biology and was drawn to the problem of cancer and what’s going on in those tumour cells that promote tumorigenesis.
Dr. Adams has a young family with three kids, all in primary school. He enjoys downhill mountain biking in the forest and playing futsal on Monday nights.
-
Professor Matthew Kiernan
BRAIN AND MIND CENTRE
@ UNIVERSITY OF SYDNEY, NEW SOUTH WALES AUSTRALIA -
Investigating the benefits of donor human milk for preterm infants
Together, SAHMRI and Lifeblood are leading a consortium to revolutionise the way human milk, and novel products made from human milk, are used as nutritional and medical interventions to improve health outcomes in vulnerable infants, but with potential application for a diverse range of medical indications.
Currently, babies who are born early preterm – before 32 weeks – are given donor milk when their own mother’s milk is not available or in short supply. Whether donor milk is beneficial for babies born just a few weeks early is unclear, as very little research has been undertaken with these babies.
The GIFT Trial will soon commence as an investigation between SAHMRI, the University of Adelaide, the Red Cross Lifeblood Milk Bank conducted at five sites across three states in Australia.
-
Life-changing donor milk for preterm babies
Dr Laura Klein is National Milk Research Leader at Australian Red Cross Lifeblood. Australian Red Cross Lifeblood is funded by Australian governments to provide life-giving blood, plasma, and transplantation and biological products.
Dr Klein works with clinicians and researchers across Australia to understand how donated breast milk can be used to improve outcomes for vulnerable babies. She’s passionate about generating evidence to improve the products and services that milk banks provide to donors and the families who receive donated breast milk.
